ArticleMolecular microbiology2017
Bordetella adenylate cyclase toxin interacts with filamentous haemagglutinin to inhibit biofilm formation in vitro.
Article in Molecular microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- A multi-epitope vaccine targetingFrontiers in immunology · 2026Article
- Interplay of virulence factors and signaling molecules: albumin and calcium-mediated biofilm regulation inJournal of bacteriology · 2025Article
- Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective againstInfection and immunity · 2024Article
- Article
- Architecture and matrix assembly determinants of Bordetella pertussis biofilms on primary human airway epithelium.PLoS pathogens · 2023Article
- Integrating proteomic data with metabolic modeling provides insight into key pathways ofFrontiers in microbiology · 2023Article
- Pathogenicity and virulence ofVirulence · 2021Review
- DegP Initiates Regulated Processing of Filamentous Hemagglutinin in Bordetella bronchiseptica.mBio · 2021Article
- Highlights of the 12th International Bordetella Symposium.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- DisruptingMicroorganisms · 2020Article
- Article
- Enhancement of immune response against Bordetella spp. by disrupting immunomodulation.Scientific reports · 2019Article
- Review
- Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.Medical microbiology and immunology · 2018Review
- Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases.Frontiers in immunology · 2018Review
- Hyperbiofilm Formation by Bordetella pertussis Strains Correlates with Enhanced Virulence Traits.Infection and immunity · 2017Article
- Article
- Bordetella Adenylate Cyclase-Hemolysin Toxins.Toxins · 2017Review
- Bacterial toxins: Offensive, defensive, or something else altogether?PLoS pathogens · 2017Review
- The Bordetella Bps Polysaccharide Is Required for Biofilm Formation and Enhances Survival in the Lower Respiratory Tract of Swine.Infection and immunity · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Bordetella pertussis, the causative agent of whooping cough, secretes and releases adenylate cyclase toxin (ACT), which is a protein bacterial toxin that targets host cells and disarms immune defenses. ACT binds filamentous haemagglutinin (FHA), a surface-displayed adhesin, and until now, the consequences of this interaction were unknown. A B. bronchiseptica mutant lacking ACT produced more biofilm than the parental strain; leading Irie et al. to propose the ACT-FHA interaction could be responsible for biofilm inhibition. Here we characterize the physical interaction of ACT with FHA and provide evidence linking that interaction to inhibition of biofilm in vitro. Exogenous ACT inhibits biofilm formation in a concentration-dependent manner and the N-terminal catalytic domain of ACT (AC domain) is necessary and sufficient for this inhibitory effect. AC Domain interacts with the C-terminal segment of FHA with ∼650 nM affinity. ACT does not inhibit biofilm formation by Bordetella lacking the mature C-terminal domain (MCD), suggesting the direct interaction between AC domain and the MCD is required for the inhibitory effect. Additionally, AC domain disrupts preformed biofilm on abiotic surfaces. The demonstrated inhibition of biofilm formation by a host-directed protein bacterial toxin represents a novel regulatory mechanism and identifies an unprecedented role for ACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.